SCHEMBL13340980

SCHEMBL13340980

CC(C)c1ccc2c(c1)OC(C)(C)C(=O)N2C(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 2/20 0.57
PGR P06401 1/20 0.36
NR3C2 P08235 1/20 0.35
PDE3B Q13370 2/20 0.33
PDE3A Q14432 2/20 0.33
NR1H3 Q13133 1/20 0.33
HPGD P15428 1/20 0.32
GFER P55789 1/20 0.32
HSD17B10 Q99714 1/20 0.32
RNASEH1 O60930 1/20 0.32
POLB P06746 1/20 0.31
KMT2A Q03164 1/20 0.31
USP2 O75604 1/20 0.31
BACE1 P56817 1/20 0.31
OPRM1 P35372 1/20 0.31
OPRK1 P41145 1/20 0.31
OPRL1 P41146 1/20 0.31
PTGER3 P43115 1/20 0.31
ALDH1A1 P00352 1/20 0.30
RARA P10276 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15786402 0.84 SLC9A1 (0.58) SLC9A1PGRNR3C2PDE3BPDE3A
SCHEMBL8738570 0.84 PDE3B (0.46) SLC9A1PGRNR3C2PDE3BPDE3A
SCHEMBL13341126 0.81 SLC9A1 (0.40) SLC9A1NR3C2NR1H3KMT2ABACE1
SCHEMBL15783472 0.80 SLC9A1 (0.55) SLC9A1PGRNR3C2PDE3BPDE3A
SCHEMBL13340916 0.80 SLC9A1 (0.39) SLC9A1PGRNR3C2POLBKMT2A
SCHEMBL20752138 0.78 SLC9A1 (0.52) SLC9A1PGRPTGER3ALDH1A1
SCHEMBL13340925 0.78 OPRD1 (0.43) SLC9A1NR3C2PDE3BPDE3APOLB
SCHEMBL13340990 0.78 SLC9A1 (0.37) SLC9A1NR3C2PDE3BPDE3ANR1H3
SCHEMBL8029177 0.76 SLC9A1 (0.66) SLC9A1POLBKMT2AUSP2ALDH1A1
SCHEMBL13340988 0.75 CRHR1 (0.36) SLC9A1NR3C2PDE3BPDE3APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9913843-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2018-03-13 US disclosed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ SLC9A1 1869/4885PGR 3225/4885NR3C2 3768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.